Article
Medicine, General & Internal
Agustin Sancho-Saldana, Anna Gil Sanchez, Bibiana Quirant-Sanchez, Lara Nogueras, Silvia Peralta, Maria Jose Solana, Cristina Gonzalez-Mingot, Yhovanni Gallego, Laura Quibus, Cristina Ramo-Tello, Silvia Presas-Rodriguez, Eva Martinez-Caceres, Pascual Torres, Jose Vicente Hervas, Joan Valls, Luis Brieva
Summary: This study found that patients with multiple sclerosis (MS) have a higher risk of COVID-19 infection compared to the general population. Disease-modifying therapies (DMTs) did not significantly affect the frequency of COVID-19, except for interferon.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Agustin Sancho-Saldana, Anna Gil-Sanchez, Cristina Gonzalez-Mingot, Silvia Peralta, Maria Jose Solana, Pascual Torres, Alba Juanes, Laura Quibus, Emilio Ruiz, Eduardo Sanpedro, Bibiana Quirant-Sanchez, Eva Martinez-Caceres, Cristina Ramo Tello, Silvia Presas-Rodriguez, Sebatian Garcia Rubio, Beatriz Pardinas Baron, Lluis Ramio-Torrenta, Javier Sotoca, Ines Gonzalez-Suarez, Sara Eichau, Jose M. Prieto-Gonzalez, Maria Rosario Blasco Quilez, Julia Sabin-Munoz, Antonio Jose Sanchez-Lopez, Gloria Llorens Calatayud, Carmen Calles, Angel Perez Sempere, Moises Garces, Olga Carmona, Ester Moral, Jose Vicente Hervas, Yolanda Blanco, Nuria Sola-Valls, Nieves Tellez Lara, Lucia Forero, Luis Brieva
Summary: This study investigates the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The results show a higher seroprevalence of SARS-CoV-2 antibodies in pwMS compared to the general population, with Interferon treatment being significantly associated with greater seroprevalence. Most pwMS in the cohort were asymptomatic for COVID-19, and even among symptomatic cases, the prognosis was generally favorable.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Multidisciplinary Sciences
Alberto Domingo Lopez-Munoz, Jefferson J. S. Santos, Jonathan W. Yewdell
Summary: We have found that the N protein of SARS-CoV-2 and HCoV-OC43 is expressed abundantly on infected and noninfected cells. It activates immune cells and inhibits leukocyte chemotaxis through different mechanisms. The N protein of HCoV-OC43 binds to a similar set of chemokines as SARS-CoV-2 N, but also binds to a distinct set of cytokines. This indicates that cell surface HCoV N plays a conserved role in manipulating host immune response.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Article
Immunology
Maryam Golshani, Jiri Hrdy
Summary: This article reviews the literature on the SARS-CoV-2 pandemic and its impact on multiple sclerosis (MS). It provides current data on the immunopathology of SARS-CoV-2 and the development of vaccines against COVID-19. It also discusses the effects of Disease Modifying Therapies (DMTs) on COVID-19 severity and vaccination in MS patients, as well as the safety profiles of different vaccine platforms in MS patients.
Article
Medicine, Research & Experimental
Joseph J. Sabatino, Kristen Mittl, William M. Rowles, Kira McPolin, Jayant Rajan, Matthew T. Laurie, Colin R. Zamecnik, Ravi Dandekar, Bonny D. Alvarenga, Rita P. Loudermilk, Chloe Gerungan, Collin M. Spencer, Sharon A. Sagan, Danillo G. Augusto, Jessa R. Alexander, Joseph L. DeRisi, Jill A. Hollenbach, Michael R. Wilson, Scott S. Zamvil, Riley Bove
Summary: A comprehensive comparison of the effects of MS DMTs on SARS-CoV-2 vaccine-specific immunity is needed, including quantitative and functional B and T cell responses.
Article
Immunology
Agata Czarnowska, Joanna Tarasiuk, Olga Zajkowska, Marcin Wnuk, Monika Marona, Klaudia Nowak, Agnieszka Slowik, Anna Jamroz-Wisniewska, Konrad Rejdak, Beata Lech, Malgorzata Popiel, Iwona Rosciszewska-Zukowska, Adam Perenc, Halina Bartosik-Psujek, Mariola Swiderek-Matysiak, Malgorzata Siger, Agnieszka Ciach, Agata Walczak, Anna Jurewicz, Mariusz Stasiolek, Karolina Kania, Klara Dyczkowska, Alicja Kalinowska-Lyszczarz, Weronika Galus, Anna Walawska-Hrycek, Ewa Krzystanek, Justyna Chojdak-Lukasiewicz, Jakub Ubysz, Anna Pokryszko-Dragan, Katarzyna Kapica-Topczewska, Marcin Bazylewicz, Anna Mironczuk, Joanna Kulikowska, Jan Kochanowicz, Marta Bialek, Malgorzata Stolarz, Katarzyna Kubicka-Baczyk, Natalia Niedziela, Natalia Morawiec, Monika Adamczyk-Sowa, Aleksandra Podlecka-Pietowska, Monika Nojszewska, Beata Zakrzewska-Pniewska, Elzbieta Jasinska, Jacek Zaborski, Marta Milewska-Jedrzejczak, Jacek Zwiernik, Beata Zwiernik, Andrzej Potemkowski, Waldemar Brola, Alina Kulakowska
Summary: Vaccination against SARS-CoV-2 is safe for people with MS who are being treated with DMTs. Most adverse events following vaccination are mild and the acute relapse incidence is low.
Article
Clinical Neurology
Afagh Garjani, Sameer Patel, Dhiren Bharkhada, Waqar Rashid, Alasdair Coles, Graham R. Law, Nikos Evangelou
Summary: This study investigated the changes in SARS-CoV-2 infection risk among patients receiving disease-modifying therapies for multiple sclerosis (MS) after vaccination. The results showed that patients taking ocrelizumab or fingolimod had a lower level of protection from the SARS-CoV-2 vaccines compared to the general population.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Review
Biochemistry & Molecular Biology
Ridhima Kaul, Pradipta Paul, Sanjay Kumar, Dietrich Buesselberg, Vivek Dhar Dwivedi, Ali Chaari
Summary: This review summarizes the activities and structure-activity relationships of flavonoids in combating SARS-CoV-2 from in vitro studies to clinical research. The study found that flavonoids such as quercetin and myricetin derivatives, baicalein, baicalin, EGCG, and tannic acid show promising activities against SARS-CoV-2.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Immunology
Yevgeniy Yuzefpolskiy, Peter Morawski, Mitch Fahning, Cate Speake, Sandra Lord, Anu Chaudhary, Chihiro Morishima, Mark H. Wener, Mariko Kita, Lucas McCarthy, Jane H. Buckner, Daniel J. Campbell, Estelle Bettelli
Summary: This study found that MS patients treated with different modifying therapies have varied immune responses to SARS-CoV-2 vaccines. B cell depletion and fingolimod therapy significantly reduced S-specific antibody response, and fingolimod therapy also compromised CD4 and CD8 T cell responses.
JOURNAL OF IMMUNOLOGY
(2022)
Review
Immunology
Johann Seliner, Paulus S. Rommer
Summary: There are concerns about using immunodepleting agents to treat MS patients during the COVID-19 pandemic, with vaccination against SARS-CoV-2 potentially being a solution. This review summarizes the immunological effects of immune-depleting therapy and discusses the existing recommendations for limited use of these therapies during the pandemic, while also critically examining questions about vaccination for MS patients.
Article
Immunology
Christina Woopen, Katharina Schleussner, Katja Akgun, Tjalf Ziemssen
Summary: This article discusses strategic approaches to SARS-CoV-2 vaccination management in multiple sclerosis (MS) patients, emphasizing the importance of measuring immune responses, especially in immunocompromised patients. Both cellular and humoral immune responses should be considered in future vaccination strategies while gaining insights into vaccine responses of immunocompromised patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Clinical Neurology
Monika Rabenstein, Olivia G. Thomas, Giorgia Carlin, Mohsen Khademi, Klara Asplund Hogelin, Clas Malmestrom, Markus Axelsson, Anne Frandsen Brandt, Guro Gafvelin, Hans Gronlund, Ingrid Kockum, Fredrik Piehl, Jan Lycke, Tomas Olsson, Tara Hessa
Summary: This study compared antibody and T-cell responses after SARS-CoV-2 mRNA vaccination in persons with MS treated with different DMTs, finding that fingolimod may suppress immune responses. Antibody and interferon gamma levels 12 weeks after vaccination were positively correlated with time from last treatment course of cladribine.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Virology
Nikolaos Spanakis, Katerina Kassela, Nikolas Dovrolis, Maria Bampali, Elisavet Gatzidou, Athanasia Kafasi, Elisavet Froukala, Anastasia Stavropoulou, Konstantinos Lilakos, Stavroula Veletza, Sotirios Tsiodras, Athanasios Tsakris, Ioannis Karakasiliotis
Summary: This study analyzed different variants of SARS-CoV-2 responsible for the outbreak in Athens before the pandemic, showing a variety of spread chains in the area, including a dominant variant and rare variants, some of which had implications for the virus's pathogenesis.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Immunology
Nandan Gautam, Shyam Madathil, Natascia Tahani, Shaun Bolton, Dhruv Parekh, James Stockley, Shraddha Goyal, Hannah Qureshi, Sadhika Yasmin, Brendan G. Cooper, Jennifer Short, Tarekegn Geberhiwot
Summary: A study found that a significant proportion of severely ill COVID-19 patients still experience symptoms such as breathlessness, fatigue, pain, reduced mobility, depression, and decreased quality of life 4-7 months after disease onset, with symptomatic patients having more residual chest radiographic and LFT abnormalities.
CLINICAL INFECTIOUS DISEASES
(2022)
Review
Clinical Neurology
Ana Munoz-Jurado, Begona M. Escribano, Eduardo Aguera, Javier Caballero-Villarraso, Alberto Galvan, Isaac Tunez
Summary: This review examines how COVID-19 affects people with Multiple Sclerosis, evaluating their risk of infection based on treatment, immune response to infection and vaccines, as well as the long-term neurological consequences. The results regarding increased infection risk due to treatment are contradictory, highlighting the need for further research.
JOURNAL OF NEUROLOGY
(2022)
Correction
Clinical Neurology
Cinzia Finocchi, Stefano Di Antonio, Matteo Castaldo, Marta Ponzano, Francesca Bovis, Jorge Hugo Villafane, Paola Torelli, Lars Arendt-Nielsen
NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Laura Fionda, Antonio Lauletta, Luca Leonardi, Jorge Alonso Perez, Stefania Morino, Gioia Merlonghi, Girolamo Alfieri, Rocco Costanzo, Laura Tufano, Fiammetta Vanoli, Elena Rossini, Eduard Gallardo Vigo, Tommaso Tartaglione, Marco Salvetti, Giovanni Antonini, Jordi Diaz-Manera, Matteo Garibaldi
Summary: This study investigates the use of muscle MRI as an outcome measure for disease activity, severity, progression, and treatment response in immune-mediated necrotizing myopathy (IMNM). The results suggest that early MRI before treatment and higher STIR% are associated with disease activity, while later MRI and higher T1 score are related to disease severity.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Darin T. Okuda, Orhun Kantarci, Christine Lebrun-Frenay, Maria Pia Sormani, Christina J. Azevedo, Francesca Bovis, Le H. Hua, Lilyana Amezcua, Ellen M. Mowry, Christophe Hotermans, Jason Mendoza, John S. Walsh, Christian von Hehn, Wendy S. Vargas, Stacy Donlon, Robert T. Naismith, Annette Okai, Gabriel Pardo, Pavle Repovic, Olaf Stuve, Aksel Siva, Daniel Pelletier
Summary: This study evaluated the impact of therapeutic intervention in preventing the first symptom manifestation in individuals with radiologically isolated syndrome (RIS), the pre-clinical phase of multiple sclerosis (MS). The results showed that drug treatment significantly reduced the risk of clinical symptoms.
ANNALS OF NEUROLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Carlo C. Quattrocchi, Marco Parillo, Federica Spani, Doriana Landi, Gaia Cola, Caterina Dianzani, Eleonora Perrella, Girolama A. Marfia, Carlo A. Mallio
Summary: This study aimed to assess the presence of detectable changes in skin thickness on brain MRI scans in patients with MS, a history of GBCAs administrations, and evidence of gadolinium deposition in the brain. Qualitative and quantitative assessment of skin thickness revealed significant differences between patients with and without evidence of gadolinium deposition.
INVESTIGATIVE RADIOLOGY
(2023)
Review
Obstetrics & Gynecology
Lorena Lorefice, Maurizio Nicola D'Alterio, Davide Firinu, Giuseppe Fenu, Eleonora Cocco
Summary: With the aging population, menopause is becoming an important turning point for women living with MS, as it can lead to increased disability accumulation and a shift towards a more progressive phase of the disease. This is attributed to the hormonal and immunological changes associated with menopause, which lead to increased neuroinflammation and neurodegeneration. It is crucial to improve the management of MS women during this multifaceted turning point and evaluate interventions to enhance their quality of life.
INTERNATIONAL JOURNAL OF WOMENS HEALTH
(2023)
Article
Clinical Neurology
Irene Schiavetti, Matilde Inglese, Jessica Frau, Elisabetta Signoriello, Francesca Caleri, Maria Laura Stromillo, Maria Teresa Ferro, Maria Teresa Rilla, Ilaria Gandoglia, Paola Gazzola, Giampaolo Brichetto, Livia Pasquali, Luigi Grimaldi, Monica Ulivelli, Fabiana Marinelli, Susanna Cordera, Marinella Clerico, Antonella Conte, Marco Salvetti, Mario Alberto Battaglia, Diego Franciotta, Antonio Uccelli, Maria Pia Sormani
Summary: This study evaluates the differences in immune response after a third vaccine dose in patients with multiple sclerosis (pwMS). The results show that patients on anti-CD20 drugs rituximab and ocrelizumab had a lower increase in antibody levels compared to patients treated with other drugs, while patients on fingolimod showed a higher increase. All pwMS increased their serum antibody levels after the third vaccine dose.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Ceren Bibinoglu Amirov, Sema Saltik, Cengiz Yalcinkaya, Melih Tutuncu, Sabahattin Saip, Aksel Siva, Ugur Uygunoglu
Summary: This study describes the use of Ocrelizumab as a disease-modifying drug for pediatric patients with relapsing-remitting multiple sclerosis (P-RRMS). The results show that Ocrelizumab can effectively reduce relapse rate and improve lesion activity, with good safety profile.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
(2023)
Correction
Clinical Neurology
Alessandro Pasquale De Rosa, Fabrizio Esposito, Paola Valsasina, Alessandro d'Ambrosio, Alvino Bisecco, Maria A. Rocca, Silvia Tommasin, Chiara Marzi, Nicola De Stefano, Marco Battaglini, Patrizia Pantano, Mario Cirillo, Gioacchino Tedeschi, Massimo Filippi, Antonio Gallo, INNI Network
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Maria Grazia Aprea, Irene Schiavetti, Emilio Portaccio, Chiara Ballerini, Mario Alberto Battaglia, Roberto Bergamaschi, Giampaolo Brichetto, S. Destan Bunul, Massimiliano Calabrese, Marco Capobianco, Paola Cavalla, Maria Grazia Celani, Marinella Clerico, Eleonora Cocco, Giancarlo Comi, Paolo Confalonieri, Antonella Conte, Cinzia Cordioli, Giovanna De Luca, Nicola De Rossi, Massimo Filippi, Haluk Gumes, Paolo Immovilli, Matilde Inglese, Rana Karabudak, Doriana Landi, Roberta Lanzillo, Maria Rita L'Episcopo, Lorena Lorefice, Vittorio Mantero, Sabrina Marangoni, Girolama Alessandra Marfia, Camilla Masciulli, Eva Milano, Lucia Moiola, Riccardo Orlandi, Francesco Patti, Paola Perini, Ilaria Pesci, Eugenio Pucci, Marco Puthenparampil, Marta Radaelli, Marco Salvetti, Arianna Sartori, Cinzia Scandellari, Sedat Sen, Aksel Siva, Silvia Strumia, Francesco Teatini, Gioacchino Tedeschi, Maria Trojano, Melih Tutuncu, Giovanna Vaula, Maria Pia Sormani, Maria Pia Amato
Summary: In this multicenter study, researchers evaluated the clinical outcomes of COVID-19 in pregnant patients with multiple sclerosis. The study found no significant increase in severe COVID-19 outcomes in multiple sclerosis patients who contracted the infection during pregnancy.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Fabiola De Marchi, Massimo Saraceno, Maria Francesca Sarnelli, Eleonora Virgilio, Roberto Cantello, Letizia Mazzini
Summary: This study aimed to investigate the correlation between vitamin D deficiency and cognitive impairment (CI) as well as clinical features in amyotrophic lateral sclerosis (ALS) patients. The results showed that most ALS patients (82%) had low levels of vitamin D, and patients with CI had even lower levels. Additionally, the study found a negative correlation between vitamin D levels and abnormal scores in cognitive assessments, as well as a positive correlation with corrected scores in the Raven's Standard Progressive Matrices test in female spinal group, and a positive correlation with direct span scores in female bulbar group. Survival analysis also revealed that patients with vitamin D levels below 10 ng/ml had shorter disease duration. Therefore, vitamin D levels may influence the cognitive status of ALS patients and severe deficiency may act as an adverse prognostic survival factor.
NEUROLOGICAL SCIENCES
(2023)
Article
Medicine, General & Internal
Domizia Vecchio, Paolo Barbero, Giulia Galli, Eleonora Virgilio, Paola Naldi, Cristoforo Comi, Roberto Cantello
Summary: This study aimed to evaluate the prognostic role of visual evoked potentials (VEPs) of the non-neuritic eye at the diagnosis of multiple sclerosis (MS). The results showed that P100 latency and N75-P100 amplitude at MS diagnosis were associated with disability at last follow-up, and P100 latency was identified as a predictor for future disability.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Neurosciences
Andrea Amerio, Luca Magnani, Carlo Castellani, Irene Schiavetti, Gabriele Sapia, Francesca Sibilla, Rita Pescini, Rosaria Casciaro, Federico Cresta, Andrea Escelsior, Alessandra Costanza, Andrea Aguglia, Gianluca Serafini, Mario Amore, Riccardo Ciprandi
Summary: The study aimed to investigate the relationship between CF and affective temperaments, taking into account the relevance of ionic balances in neural excitability as a potential neurobiological basis for temperamental expression. The study involved 55 adult CF patients and evaluated various factors including sociodemographic, clinical and therapeutic characteristics, temperamental and personality dispositions, and depressive and anxiety symptoms. The results showed that a hyperthymic temperament was protective against psychopathology, while other temperaments were associated with positive psychopathological history.
Article
Immunology
P. Caria, S. Pilotto, M. N. D'Alerto, M. Fronza, F. Murgia, J. Frau, G. Fenu, T. Dettori, D. V. Frau, L. Atzori, S. Angioni, E. Cocco, L. Lorefice
Summary: This study investigated the changes of leukocyte telomere length (LTL) in women with multiple sclerosis (MS) and its relationship with MS activity. The results showed that LTL of MS women during pregnancy was significantly shorter than that of healthy women. Furthermore, the shortening of LTL was associated with MS reactivation.
JOURNAL OF NEUROIMMUNOLOGY
(2023)
Article
Clinical Neurology
Sedat Sen, Asli Tuncer, Murat Terzi, Sena Destan Bunul, Pinar Ozen-Acar, Burcu Altunrende, Serkan Ozakbas, Melih Tutuncu, Ugur Uygunoglu, Gulsen Akman-Demir, Rana Karabudak, Husnu Efendi, Aksel Siva
Summary: This study evaluated the prognosis and outcomes of Turkish patients with AQP4-IgG+ NMOSD who received Eculizumab treatment. The findings suggest that Eculizumab is effective and safe for patients with high disease activity, but disease reactivation may occur after discontinuation of the treatment.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Pediatrics
Elia Manfrini, Ludovica Falcioni, Vanna Cavassa, Eleonora Cocco, Stefano Sotgiu, Luca Saba
Summary: Here we present a 17-year-old girl with nausea, vomiting, and vertigo. Neurological examination revealed central nystagmus, positive Romberg's test, and left-sided hyperreflexia. Magnetic resonance imaging showed bilateral demyelinating lesions at the trigeminal root of the fifth nerve, fulfilling the criteria for multiple sclerosis.
JOURNAL OF PEDIATRIC NEUROLOGY
(2023)